Assessing IRADIMED (IRMD) Valuation After Strong Long Term Returns And Premium Earnings Multiple

IRADIMED stock triggered article

With no single headline event driving attention today, IRADIMED (IRMD) is drawing interest for its recent share performance and financial profile. The stock had a last close of US$92.10 and a market value near US$1.18b.

See our latest analysis for IRADIMED.

Recent trading has been choppy, with the share price falling 1.15% over the last day but up 6.55% over the past week and down 8.84% over 90 days, while the 1 year total shareholder return of 82.78% and 5 year total shareholder return of 263.83% point to strong long term momentum.

If IRADIMED’s move has you thinking about healthcare technology more broadly, this may be a moment to scan for other potential opportunities through our healthcare AI stock screener, starting with 34 healthcare AI stocks.

With IRADIMED posting 1 year and 5 year total returns well ahead of many stocks and trading about 28% below one analyst price target, it raises the key question: is there still an opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 22.4% Undervalued

IRADIMED’s most followed narrative points to a fair value of $118.67, which sits well above the latest close at $92.10 and frames the current debate.

The introduction and FDA approval of the new 3870 MRI-compatible IV pump, with significantly enhanced usability and technology over the legacy product, is expected to catalyze a major replacement cycle among hospitals and imaging centers, unlocking large-scale, recurring device and consumable revenues. This supports a step-change in revenue growth as existing customers upgrade and potential new customers previously deterred by usability issues are attracted.

Read the complete narrative.

Curious what sits behind that confidence in higher future earnings and margins, and the rich profit multiple that underpins the $118.67 fair value? The narrative leans heavily on sustained double digit growth, an elevated long term profitability profile, and a premium valuation multiple that assumes the market keeps rewarding that trajectory.

Result: Fair Value of $118.67 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this upbeat narrative still depends heavily on a narrow product range and smooth execution, so any supply chain issues or slower hospital spending could quickly challenge it.

Find out about the key risks to this IRADIMED narrative.

Another Angle On IRADIMED’s Valuation

The bullish narrative leans heavily on future earnings to argue IRADIMED is undervalued, yet today the stock trades on a P/E of 49.9x. That is well above the US Medical Equipment industry at 24.5x, peers at 39.8x, and a fair ratio of 19.8x. If sentiment cools and the market drifts closer to that fair ratio, current buyers could face meaningful valuation risk. Which story do you think the market will lean into next?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of optimism and caution resonates with you, take a moment to review the key numbers yourself and see how they stack up against expectations, then weigh up the company’s 2 key rewards

Looking for more investment ideas?

If IRADIMED has caught your eye, do not stop there. Widening your watchlist with a few targeted screeners can reveal opportunities you would otherwise miss.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com